Quantinno Capital Management LP Has $1.94 Million Stake in Axsome Therapeutics, Inc. $AXSM

Quantinno Capital Management LP increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 77.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,497 shares of the company’s stock after purchasing an additional 5,019 shares during the quarter. Quantinno Capital Management LP’s holdings in Axsome Therapeutics were worth $1,943,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock worth $275,763,000 after buying an additional 472,422 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after buying an additional 609,516 shares during the period. Invesco Ltd. increased its stake in shares of Axsome Therapeutics by 28.6% in the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after buying an additional 282,937 shares during the period. Geode Capital Management LLC raised its position in shares of Axsome Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock worth $184,544,000 after acquiring an additional 12,549 shares during the last quarter. Finally, State Street Corp raised its position in shares of Axsome Therapeutics by 5.8% during the second quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after acquiring an additional 52,483 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AXSM. Morgan Stanley upped their price target on Axsome Therapeutics from $242.00 to $251.00 and gave the company an “equal weight” rating in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $272.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Guggenheim raised their target price on shares of Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada dropped their price target on shares of Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $267.10.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Auvelity continues to drive growth. Second-quarter net product revenue increased 46% year over year, led primarily by Auvelity sales. Growth benefited from the product’s expanded use in Alzheimer’s disease agitation and a larger commercial sales force. Axsome’s Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
• Positive Sentiment: Pipeline ambitions support the long-term outlook. Management said it expects to file approximately one new drug application annually through 2030. AXS-12 is currently targeting a May 1, 2027 PDUFA date, providing a potential future catalyst. Axsome signals one NDA per year through 2030
• Positive Sentiment: Needham raised its price target. Needham increased its target from $267 to $268 and maintained a Buy rating, implying substantial upside based on the cited reference price. Needham raises Axsome price target
• Neutral Sentiment: Reported short-interest data appear unreliable. The update lists zero short interest both currently and in the prior period, along with a zero-day days-to-cover ratio, so it provides no meaningful signal about investor positioning.
• Negative Sentiment: Quarterly results missed on both key measures. Axsome reported a loss of $0.99 per share versus the $0.89 consensus estimate and revenue of $218.38 million versus expectations of $221.11 million. The company remains unprofitable, with rising SG&A expenses offsetting much of its commercial progress. Axsome second-quarter earnings results
• Negative Sentiment: Valuation and execution concerns remain. Analysts and investors are questioning whether management’s roughly $8 billion peak-sales target for Auvelity is achievable, particularly as commercialization costs rise and profitability remains elusive.

Insider Activity at Axsome Therapeutics

In related news, Director Roger Jeffs sold 286 shares of the business’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the sale, the director directly owned 58,653 shares of the company’s stock, valued at approximately $14,439,195.54. The trade was a 0.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mark Coleman sold 643 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the transaction, the director directly owned 30,389 shares of the company’s stock, valued at approximately $7,566,861. The trade was a 2.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 200,766 shares of company stock valued at $46,685,646 over the last three months. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $215.77 on Wednesday. The stock has a 50 day simple moving average of $236.64 and a 200 day simple moving average of $204.60. Axsome Therapeutics, Inc. has a 52-week low of $103.40 and a 52-week high of $260.19. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The firm has a market capitalization of $11.10 billion, a PE ratio of -57.54 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 275.76% and a negative net margin of 24.68%.The company had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. Sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.